XML 22 R12.htm IDEA: XBRL DOCUMENT
v3.21.2

Share-Based Payments | 6 Months Ended
--- | ---
Oct. 31, 2021
Share-based Payment Arrangement [Abstract] |
Share-Based Payments | Share-Based Payments The Company has in place a 2010 Equity Incentive Plan, 2008 Equity Incentive Plan and 2021 Equity Incentive Plan. In general, these plans provide for stock-based compensation in the form of (i) Non-statutory Stock Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights to the Company’s employees, directors and non-employees. The plans also provide for limits on the aggregate number of shares that may be granted, the term of grants and the strike price of option awards. Stock-based compensation expense was recognized as follows (table in thousands):
| Three Months Ended October 31, |  | Six Months Ended October 31, |  |
| 2021 |  | 2020 |  | 2021 |  | 2020 |  |  |  |
General and administrative | $ | 48 |  |  | $ | 10 |  |  | $ | 219 |  |  | $ | 57 |  |  |  |  |
Sales and marketing | 45 |  |  | 49 |  |  | 96 |  |  | 97 |  |  |  |  |
Research and development | 8 |  |  | 5 |  |  | 14 |  |  | 9 |  |  |  |  |
Cost of oncology services | 33 |  |  | 21 |  |  | 85 |  |  | 42 |  |  |  |  |
Total stock-based compensation expense | $ | 134 |  |  | $ | 85 |  |  | $ | 414 |  |  | $ | 205 |  |  |  |  |
Stock Option Grants Black-Scholes assumptions used to calculate the fair value of options granted during the three and six months ended October 31, 2021 and 2020 were as follows:
| Three Months Ended October 31, |  | Six Months Ended October 31, |  |
| 2021 |  | 2020 |  | 2021 |  | 2020 |  |  |  |
Expected term in years | — |  | 6 |  | 6 |  | 6 |  |  |  |
Risk-free interest rates | —% |  | 0.27% | 0 | 0.82%-—% |  | 0.27%-0.39% |  |  |  |
Volatility | —% |  | 72.83% |  | 65.94%-66.21% |  | 72.64%-72.83% |  |  |  |
Dividend yield | —% |  | —% |  | —% |  | —% |  |  |  |
The weighted average fair value of stock options granted during the three and six months ended October 31, 2020 was $7.05 and $7.29, respectively. There was no options granted during the three months ended October 31, 2021. The weighted average fair value of stock options granted during the six months ended October 31, 2021 was $5.33. The Company’s stock options activity for the six months ended October 31, 2021 was a s follows:
| Directors and Employees | Non- Employees |  |  | Total |  | Weighted Average Exercise Price |  | Weighted Average Remaining Contractual Life (Years) |  | Aggregate Intrinsic Value
Outstanding, April 30, 2021 | 1,618,231 |  | 35,415 |  |  |  | 1,653,646 |  |  | $ | 3.96 |  |  | 5.42 |  | $ | 11,384,000 |
Granted | 82,532 |  | 3,000 |  |  |  | 85,532 |  |  | 9.01 |  |  | 9.65 |  |
Exercised | (82,078) |  | — |  |  |  | (82,078) |  |  | 1.91 |  |  |  |  |
Forfeited | (12,500) |  | — |  |  |  | (12,500) |  |  | 6.74 |  |  |  |  |
Canceled | (4,672) |  | — |  |  |  | (4,672) |  |  | 3.36 |  |  |  |  |
Expired | — |  | (5,000) |  |  |  | (5,000) |  |  | 9.60 |  |  |  |  |
Outstanding, October 31, 2021 | 1,601,513 |  | 33,415 |  |  |  | 1,634,928 |  |  | 4.29 |  |  | 5.27 |  | $ | 9,246,000 |
Vested and expected to vest as of October 31, 2021 | 1,601,513 |  | 33,415 |  |  |  | 1,634,928 |  |  | 4.29 |  |  | 5.27 |  | $ | 9,246,000 |
Exercisable as of October 31, 2021 | 1,296,094 |  | 4,584 |  |  |  | 1,300,678 |  |  | 3.69 |  |  | 4.51 |  | $ | 8,189,000 |

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration